MetaCap

Korro Bio (KRRO) vs Vogenx (VOGX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Vogenx is the larger company by market cap ($176.3 million vs $167.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KRRO-8.76%VOGX-8.69%
+172%+63%-46%
Aug 12, 20261 yearNov 20, 2026
KRRO-8.28%VOGX-19.69%
+138%+47%-44%
Aug 10, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KRRO versus VOGX key metrics
MetricKRROVOGX
Share price$12.18$11.87
Market cap$167.18M$176.33M
1-day change-0.08%-7.30%
YTD return+52.06%—
1-year return+93.95%—
5-year return-95.67%—
EPS (TTM)$-8.89$-0.89
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$6.39M—
Revenue growth (YoY)+181.46%—
Net income (latest FY)$-117.26M—
Operating margin-1906.37%—
Net margin-1834.48%—
52-week high$17.35$38.41
52-week low$5.20$11.51
Distance from 52-week high-29.81%-69.10%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+76.52%+363.35%
Average volume186.03K128.78K
Shares outstanding13.73M14.86M
Employees584
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Korro Bio

KRRO stock →

Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia.

Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees

About Vogenx

VOGX stock →

Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

KRRO vs VOGX FAQ

Which is bigger, Korro Bio or Vogenx?

Vogenx (VOGX) is larger, with a market capitalization of $176.33M compared with $167.18M for Korro Bio (KRRO).

Are Korro Bio and Vogenx in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons